AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aurinia Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.49−0.02 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
58.7%
78M of 133M shares
Institutional holders
281
49 new, 24 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
11 buys · 2 sales
Net bought $24.60M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,921,049 | 6.20% | 13G (passive) amendment | Dec 31, 2023 |
| Tang Capital Management, LLC | 13,044,106 | 10.00% | 13D (active) amendment | Jun 2, 2026 |
| Kevin Tang | 10,029,500 | 7.30% | 13D (active) amendment | Feb 28, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AUPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 13,044,106 | 9.80% | $221.36M | +814,606 | 10.05% |
| BlackRock, Inc. | 8,193,085 | 6.16% | $139.04M | +347,564 | 0.00% |
| Goldman Sachs Group Inc | 5,619,401 | 4.22% | $95.36M | +4,185,893 | 0.01% |
| NEA Management Company, LLC | 3,969,834 | 2.98% | $67.37M | – | 4.24% |
| Two Sigma Investments, LP | 3,467,514 | 2.61% | $58.84M | +38,809 | 0.04% |
| Arrowstreet Capital, Limited Partnership | 3,264,062 | 2.45% | $55.39M | −20,306 | 0.02% |
| State Street Corp | 2,589,615 | 1.95% | $43.95M | +62,516 | 0.00% |
| Morgan Stanley | 2,308,244 | 1.73% | $39.17M | +75,696 | 0.00% |
| Marshall Wace, Llp | 2,044,007 | 1.54% | $34.69M | +169,410 | 0.03% |
| Geode Capital Management, LLC | 1,701,152 | 1.28% | $28.86M | +165,143 | 0.00% |
| Renaissance Technologies LLC | 1,548,035 | 1.16% | $26.27M | −115,800 | 0.04% |
| D. E. Shaw & Co., Inc. | 1,408,456 | 1.06% | $23.90M | −164,527 | 0.01% |
| Vanguard Portfolio Management LLC | 1,359,028 | 1.02% | $23.06M | +102,667 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,231,516 | 0.93% | $20.90M | +134,327 | 0.08% |
| Jupiter Asset Management Ltd | 1,094,475 | 0.82% | $18.57M | +291,056 | 0.09% |
| Lsv Asset Management | 1,079,447 | 0.81% | $18.32K | +39,871 | 0.03% |
| Nomura Holdings Inc | 978,602 | 0.74% | $16.61M | +9,692 | 0.02% |
| Aqr Capital Management LLC | 948,751 | 0.71% | $16.10M | −59 | 0.01% |
| Northern Trust Corp | 863,567 | 0.65% | $14.65M | +39,462 | 0.00% |
| Nuveen, LLC | 812,915 | 0.61% | $13.80M | +159,491 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 281 | 78M | 58.7% | 49 / 105 | 80 / 24 | 11M | 6M |
| Q1 2026 | 260 | 74M | 55.6% | 40 / 104 | 71 / 29 | 10M | 6M |
| Q4 2025 | 256 | 73M | 54.6% | 45 / 89 | 82 / 29 | 12M | 6M |
| Q3 2025 | 242 | 67M | 50.0% | 47 / 62 | 91 / 20 | 15M | 8M |
| Q2 2025 | 219 | 59M | 44.4% | 34 / 69 | 63 / 28 | 7M | 11M |
| Q1 2025 | 214 | 63M | 47.2% | 38 / 67 | 59 / 21 | 11M | 6M |
| Q4 2024 | 200 | 59M | 44.0% | 38 / 63 | 51 / 19 | 7M | 8M |
| Q3 2024 | 183 | 59M | 44.4% | 31 / 52 | 46 / 16 | 19M | 7M |
| Q2 2024 | 171 | 57M | 42.5% | 25 / 57 | 47 / 31 | 6M | 8M |
| Q1 2024 | 178 | 59M | 44.1% | 27 / 47 | 62 / 39 | 9M | 6M |
| Q4 2023 | 191 | 56M | 41.8% | 22 / 60 | 64 / 26 | 12M | 6M |
| Q3 2023 | 198 | 51M | 38.4% | 24 / 69 | 49 / 23 | 8M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AUPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 3,062,402 | 2.30% | $51.97M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,303,109 | 0.98% | $19.39M | 0.06% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,101,324 | 0.83% | $18.69M | 0.12% | Jun 30, 2026 |
| iShares Biotechnology ETF | 800,933 | 0.60% | $13.59M | 0.15% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 613,258 | 0.46% | $9.40M | 0.05% | May 31, 2026 |
| Goldman Sachs U.S. Tax-Managed Equity Fund | 541,443 | 0.41% | $9.19M | 0.19% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 480,650 | 0.36% | $7.15M | 0.18% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 336,035 | 0.25% | $5.15M | 0.03% | May 31, 2026 |
| Goldman Sachs Small Cap Value Insights Fund | 334,685 | 0.25% | $4.98M | 0.38% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 321,869 | 0.24% | $5.46M | 0.09% | Jun 30, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 304,118 | 0.23% | $4.53M | 0.45% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 288,413 | 0.22% | $4.29M | 0.06% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 241,157 | 0.18% | $3.70M | 0.13% | May 31, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 237,798 | 0.18% | $3.54M | 0.42% | Jul 31, 2026 |
| Master Small Cap Index Series | 216,179 | 0.16% | $3.67M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kevin Tang | Chief Executive Officer, Director, 10% owner | 13,044,106 | 9.80% | Jun 2, 2026 |
| Peter Greenleaf | Chief Executive Officer, Director | 1,840,379 | 1.38% | Mar 3, 2026 |
| Stephen P. Robertson | Chief Legal Officer | 588,848 | 0.44% | Sep 11, 2026 |
| Ryan Cole | Chief Operating Officer | 116,144 | 0.09% | May 20, 2026 |
| Michael S. Hearne | Chief Financial Officer | 116,144 | 0.09% | May 20, 2026 |
| Greg Keenan | SVP, Chief Medical Officer | 154,449 | 0.12% | Mar 10, 2026 |
| Joseph M. Miller | Chief Financial Officer | 576,421 | 0.43% | Mar 3, 2026 |
| Matthew Maxwell Donley | Chief Operating Officer | 680,299 | 0.51% | Mar 3, 2026 |
| Kathleen Goetz | Director | – | – | Jun 8, 2026 |
| Craig A. Johnson | Director | 14,592 | 0.01% | Jun 8, 2026 |
| Jeffrey Allen Bailey | Director | 22,775 | 0.02% | Jun 8, 2026 |
| Tina Susan Nova | Director | – | – | Jun 8, 2026 |
| Karen L. Smith | Director | 24,807 | 0.02% | Nov 25, 2024 |
| David R.W. Jayne | Director | 56,499 | 0.04% | Nov 25, 2024 |
| Jill Leversage | Director | 26,453 | 0.02% | Nov 25, 2024 |
| Capital Management Llc Tang | 10% owner | – | – | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen P. Robertson Chief Legal Officer | Sep 10, 2026 | Sale | −11,939 | $15.95 | $190.43K | 588,848 |
| Stephen P. Robertson Chief Legal Officer | Aug 21, 2026 | Sale | −20,975 | $16.97 | $355.95K | 600,787 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | Jun 2, 2026 | Buy | +206,005 | $15.28 | $3.15M | 13,044,106 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | Jun 1, 2026 | Buy | +99 | $15.34 | $1.52K | 12,838,101 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | Jun 1, 2026 | Buy | +343,521 | $15.28 | $5.25M | 12,838,002 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | May 29, 2026 | Buy | +262,682 | $15.31 | $4.02M | 12,494,481 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | May 29, 2026 | Buy | +2,299 | $15.35 | $35.29K | 12,231,799 |
| Ryan Cole Chief Operating Officer | May 18, 2026 | Award | +116,144 | – | – | 116,144 |
| Stephen P. Robertson Chief Legal Officer | May 18, 2026 | Award | +115,541 | – | – | 621,402 |
| Michael S. Hearne Chief Financial Officer | May 18, 2026 | Award | +116,144 | – | – | 116,144 |
| Greg Keenan SVP, Chief Medical Officer | Mar 6, 2026 | Tax withholding | −8,069 | $14.32 | $115.55K | 154,449 |
| Kevin Tang Director | Mar 3, 2026 | Buy | +184,208 | $14.22 | $2.62M | 12,229,500 |
| Stephen P. Robertson EVP, General Counsel | Mar 2, 2026 | Tax withholding | −36,525 | $14.21 | $519.02K | 505,861 |
| Joseph M. Miller Chief Financial Officer | Mar 2, 2026 | Tax withholding | −37,511 | $14.21 | $533.03K | 576,421 |
| Peter Greenleaf Chief Executive Officer, Director | Mar 2, 2026 | Tax withholding | −100,890 | $14.21 | $1.43M | 1,840,379 |
| Kevin Tang Director | Mar 2, 2026 | Buy | +115,792 | $14.21 | $1.65M | 12,045,292 |
| Kevin Tang Director | Mar 2, 2026 | Buy | +83,561 | $14.33 | $1.20M | 11,929,500 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 2, 2026 | Tax withholding | −40,761 | $14.21 | $579.21K | 680,299 |
| Stephen P. Robertson EVP, General Counsel | Feb 27, 2026 | Award | +59,090 | – | – | 542,386 |
| Joseph M. Miller Chief Financial Officer | Feb 27, 2026 | Award | +57,229 | – | – | 613,932 |
| Peter Greenleaf Chief Executive Officer, Director | Feb 27, 2026 | Award | +196,403 | – | – | 1,941,269 |
| Kevin Tang Director | Feb 27, 2026 | Buy | +300,000 | $13.90 | $4.17M | 11,629,500 |
| Kevin Tang Director | Feb 27, 2026 | Buy | +1,600 | $14.38 | $23.01K | 11,845,939 |
| Kevin Tang Director | Feb 27, 2026 | Buy | +214,839 | $14.12 | $3.03M | 11,844,339 |
| Greg Keenan SVP, Chief Medical Officer | Feb 27, 2026 | Award | +40,586 | – | – | 162,518 |
| Matthew Maxwell Donley Chief Operating Officer | Feb 27, 2026 | Award | +58,160 | – | – | 721,060 |
| Stephen P. Robertson EVP, General Counsel | Feb 20, 2026 | Tax withholding | −34,638 | $14.40 | $498.79K | 483,296 |
| Joseph M. Miller Chief Financial Officer | Feb 20, 2026 | Tax withholding | −32,424 | $14.40 | $466.91K | 556,703 |
| Matthew Maxwell Donley Chief Operating Officer | Feb 20, 2026 | Tax withholding | −32,901 | $14.40 | $473.77K | 662,900 |
| Peter Greenleaf Chief Executive Officer, Director | Feb 20, 2026 | Tax withholding | −100,171 | $14.40 | $1.44M | 1,744,866 |
| Greg Keenan SVP, Chief Medical Officer | Feb 2, 2026 | Tax withholding | −11,552 | $14.53 | $167.85K | 121,932 |
| Stephen P. Robertson EVP, General Counsel | Jan 2, 2026 | Tax withholding | −40,385 | $15.95 | $644.14K | 517,934 |
| Stephen P. Robertson EVP, General Counsel | Jan 2, 2026 | Award | +48,558 | – | – | 557,434 |
| Peter Greenleaf Chief Executive Officer, Director | Jan 2, 2026 | Award | +165,384 | – | – | 1,954,329 |
| Peter Greenleaf Chief Executive Officer, Director | Jan 2, 2026 | Tax withholding | −113,169 | $15.95 | $1.81M | 1,845,037 |
| Joseph M. Miller Chief Financial Officer | Jan 2, 2026 | Tax withholding | −40,161 | $15.95 | $640.57K | 589,127 |
| Joseph M. Miller Chief Financial Officer | Jan 2, 2026 | Award | +49,038 | – | – | 626,399 |
| Matthew Maxwell Donley Chief Operating Officer | Jan 2, 2026 | Award | +54,166 | – | – | 734,631 |
| Matthew Maxwell Donley Chief Operating Officer | Jan 2, 2026 | Tax withholding | −42,787 | $15.95 | $682.45K | 695,801 |
| Jeffrey Allen Bailey Director | Nov 21, 2025 | Tax withholding | −2,716 | $15.68 | $42.59K | 22,775 |
| Craig A. Johnson Director | Nov 21, 2025 | Tax withholding | −6,039 | $15.68 | $94.69K | 14,592 |
| Kevin Tang Director | Aug 5, 2025 | Buy | +200,000 | $11.68 | $2.34M | 11,329,500 |
| Kevin Tang Director | Aug 4, 2025 | Buy | +100,000 | $11.34 | $1.13M | 11,129,500 |
| Greg Keenan Chief Medical Officer | Aug 1, 2025 | Sale | −20,000 | $10.50 | $210.00K | 133,484 |
| Kevin Tang Director | Aug 1, 2025 | Buy | +1,000,000 | $10.12 | $10.12M | 11,029,500 |
| Greg Keenan Chief Medical Officer | Mar 7, 2025 | Sale | −8,305 | $8.23 | $68.35K | 153,484 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 4, 2025 | Sale | −58,991 | $7.92 | $467.21K | 680,465 |
| Stephen P. Robertson EVP, General Counsel | Mar 4, 2025 | Sale | −57,607 | $7.92 | $456.25K | 509,276 |
| Kevin Tang Director | Mar 4, 2025 | Buy | +148,038 | $8.00 | $1.18M | 9,429,500 |
| Kevin Tang Director | Mar 4, 2025 | Buy | +500,000 | $7.92 | $3.96M | 9,929,500 |
| Kevin Tang Director | Mar 4, 2025 | Buy | +100,000 | $8.09 | $809.00K | 10,029,500 |
| Joseph M. Miller Chief Financial Officer | Mar 4, 2025 | Sale | −56,154 | $7.92 | $444.74K | 577,361 |
| Peter Greenleaf Chief Executive Officer, Director | Mar 4, 2025 | Sale | −164,947 | $7.92 | $1.31M | 1,788,945 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 3, 2025 | Award | +135,567 | – | – | 805,358 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 3, 2025 | Sale | −65,902 | $8.00 | $527.22K | 739,456 |
| Greg Keenan Chief Medical Officer | Mar 3, 2025 | Sale | −12,239 | $8.00 | $97.91K | 161,789 |
| Stephen P. Robertson EVP, General Counsel | Mar 3, 2025 | Award | +102,406 | – | – | 631,755 |
| Stephen P. Robertson EVP, General Counsel | Mar 3, 2025 | Sale | −64,872 | $8.00 | $518.98K | 566,883 |
| Kevin Tang Director | Mar 3, 2025 | Buy | +351,962 | $8.02 | $2.82M | 9,281,462 |
| Kevin Tang Director | Mar 3, 2025 | Buy | +100,720 | $7.97 | $802.74K | 8,929,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| P. Robertson Stephen Officer | Aug 21, 2026 | 47,000 | $719.10K | Aug 21, 2026 | Performance Stock Units |
| Keenan Gregory Former Affiliate | Jun 5, 2026 | 9,593 | $158.49K | Jun 5, 2026 | Exercise of Options Under a Registered Plan |
| Keenan Gregory Former Affiliate | Jun 4, 2026 | 25,000 | $408.44K | Jun 4, 2026 | Exercise of Options Under a Registered Plan |
| Keenan Gregory Officer | Jun 2, 2026 | 25,000 | $54.10M | Jun 2, 2026 | Exercise of options under a registered plan |
| Greenleaf Peter Former Affiliate | May 11, 2026 | 3,136,201 | $49.68M | May 11, 2026 | Exercise of options under a registered plan |
| Maxwell Donley Matthew Former Affiliate | May 11, 2026 | 717,688 | $11.37M | May 11, 2026 | Exercise of options under a registered plan |
| Miller Joseph Former Affiliate | May 11, 2026 | 500,503 | $7.93M | May 11, 2026 | Exercise of options under a registered plan |